Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.
Press releases published on April 1, 2025
IVF Specialists Now Recommend Single Embryo Transfer for Safer, Healthier Pregnancies
EIN Presswire
·
April 1, 2025
IVF experts now recommend single embryo transfer (SET) for safer pregnancies, reducing risks while maintaining high success rates. NEW YORK, NY, UNITED STATES, April 1, 2025 /EINPresswire.com/ -- Surrogacy4All.com, a leading surrogacy agency and …
ES Clinical Research Group Supports Clinical Trial Sites and Physicians Nationwide
EIN Presswire
·
April 1, 2025
ES Clinical Research Group supports US clinical trial sites and physicians, providing comprehensive management for Phase I-IV trials. FRESH MEADOWS, NY, UNITED STATES, April 1, 2025 /EINPresswire.com/ -- ES Clinical Research Group, a Site Management …
USA Fibroid Study: Outpatient UAE Delivers Dramatic Quality of Life Improvement
EIN Presswire
·
April 1, 2025
Non-surgical UAE significantly improves fibroid patient quality of life in outpatient settings, landmark research shows. NEW YORK, NY, UNITED STATES, April 1, 2025 /EINPresswire.com/ -- A landmark clinical study published in Diagnostics has confirmed …
Andros Introduces Network Transformation Team to Drive Provider Network Innovation
EIN Presswire
·
April 1, 2025
Andros launches Network Transformation Team to help health plans optimize every stage of the network lifecycle with data-driven strategies and expertise. NEW YORK, NY, UNITED STATES, April 1, 2025 /EINPresswire.com/ -- Andros, the healthcare industry’s …
Portsmouth Square Completes Strategic Refinancing of Hilton San Francisco Financial District Hotel
GlobeNewswire
·
April 1, 2025
SAN FRANCISCO, CA, April 01, 2025 (GLOBE NEWSWIRE) -- Portsmouth Square, Inc. (OTC: PRSI) ("Portsmouth Square" or "the Company") today announced the successful refinancing of its flagship asset, the Hilton San Francisco Financial District Hotel. This …
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order
GlobeNewswire
·
April 1, 2025
TORONTO, ONTARIO, April 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and …
CDC Layoffs Deliver Devastating Blow to Respiratory Health
GlobeNewswire
·
April 1, 2025
Washington, DC, April 01, 2025 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is deeply concerned about recent reductions in force (RIFs) at the Centers for Disease Control and Prevention (CDC), which put critical public health …
HNF-Funded Wearable Sensor Study to Be Presented at the 2025 AAN Annual Meeting
EIN Presswire
·
April 1, 2025
HNF remains dedicated to funding and supporting innovative research efforts that improve the lives of those living with CMT and other neuromuscular disorders. NEW YORK, NY, UNITED STATES, April 1, 2025 /EINPresswire.com/ -- The Hereditary Neuropathy …
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 1, 2025
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other …
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
GlobeNewswire
·
April 1, 2025
Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from NATiV3 projected in the second half of 2026 and, if positive, expected to be the basis for submission for regulatory …
Inventiva annonce la fin du recrutement de l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor chez les patients atteints de MASH et de fibrose avancée
GlobeNewswire
·
April 1, 2025
Objectifs de recrutement dépassés avec 1.009 patients randomisés dans la cohorte principale et 411 dans la cohorte exploratoire Principaux résultats de NATiV3 attendus au deuxième semestre 2026 et, si positifs, ils supporteront les demandes règlementaires …
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire
·
April 1, 2025
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that the Compensation and Human …
Pennant Expands Portfolio with Acquisition of Senior Living Community in Arizona
GlobeNewswire
·
April 1, 2025
EAGLE, Idaho, April 01, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announces the acquisition of the real estate and …
BioStem Technologies Announces Extension to File 2024 Annual Report with OTC
GlobeNewswire
·
April 1, 2025
POMPANO BEACH, Fla., April 01, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces …
Venus Concept Announces $11 million Debt-to-Equity Exchange Transaction
GlobeNewswire
·
April 1, 2025
TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that, on March 31, 2025, the Company exchanged $11.0 million of its subordinated …
HCW Biologics Announces 1-for-40 Reverse Stock Split
GlobeNewswire
·
April 1, 2025
MIRAMAR, Fla., April 01, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by …
Respilean Review (BREAKING NEWS): Why Thousands Are Calling It the Natural Lung Breakthrough of 2025
GlobeNewswire
·
April 1, 2025
DENVER, April 01, 2025 (GLOBE NEWSWIRE) -- In a world where we measure everything—from step counts to calories—there’s one thing we rarely track until it’s already compromised: our lung health. With pollution rising, allergens becoming more aggressive, and …
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
GlobeNewswire
·
April 1, 2025
Two posters will share data on the significant risk stratification provided by DecisionDx-Melanoma in a real-world cohort of patients with stage IIB-IIC cutaneous melanoma (CM) to help guide adjuvant therapy, and the role of the test in prompting use of …
Viscogliosi Brothers Completes Acquisition of U.S. Spine Business from Stryker, Creating VB Spine, LLC
GlobeNewswire
·
April 1, 2025
VB Spine is a Strategic Partner to Stryker with Access to Mako Spine and Copilot Marc, John and Anthony Viscogliosi Lead VB Spine as Co-Chief Executive Officers NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Viscogliosi Brothers, LLC, a family-owned …
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 1, 2025
FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in …